Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Xevinapant and Chemoradiotherapy in Adjuvant Treatment for Patients With Head and Neck Squamous Cell Carcinoma With High Risk Pathologic Features

NCT06084845 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT06084845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06084845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Xevinapant and Chemoradiotherapy in Adjuvant Treatment for Patients With Head and Neck Squamous Cell Carcinoma With High Risk Pathologic Features
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Withdrawn
Start date
April 12, 2024
Completion date
May 31, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharyngeal squamous cell carcinoma, stage iii cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iii hypopharyngeal carcinoma ajcc v8, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8